<DOC>
	<DOCNO>NCT00101426</DOCNO>
	<brief_summary>This safety efficacy trial ranirestat ( AS-3201 ) aldose reductase inhibitor patient diabetic sensorimotor polyneuropathy .</brief_summary>
	<brief_title>Safety Efficacy AS-3201 Treatment Diabetic Sensorimotor Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Patients follow may enter : Clinical sign symptom ( footpain , numbness , tingle , weakness , etc . ) symmetrical distal Diabetic Sensorimotor Polyneuropathy diagnosis Nerve Conduction Tests and/or Quantitative Sensory Test . 18 70 year old either sex race Type I Type II , insulindependent non insulindependent diabetes least six month prior study entry Healthy general No hospitalization diabetic control episodes ketoacidosis three month prior screen Female patient childbearing potential must negative serum pregnancy test Known nondiabetic cause neuropathic symptom Diabetic patient neuropathy severe neuropathy Used Aldose Reductase Inhibitors within one year screen Clinically significant illness include unstable cardiac , pulmonary , hematologic , hepatic , renal , neoplastic disease A history systemic carcinoma within five year screen A history epilepsy serious head injury A history evidence drug alcohol abuse Test positive screening hepatitis B surface antigen hepatitis C antibody history positive result , patient evidence significant hepatic insufficiency A history know suspected diagnosis AIDS , test seropositive HIV antibody antigen previously</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Diabetic sensorimotor polyneuropathy</keyword>
	<keyword>Diabetic Neuropathy</keyword>
</DOC>